| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в січні 1997 (uk)
- article scientifique publié en 1997 (fr)
- im Januar 1997 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en xineru de 1997 (ast)
- artikull shkencor i botuar më 01 janar 1997 (sq)
- scientific article published on 01 January 1997 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - H Sun
- R Williams
- V Shah
- A Hussain
- M Hossain
- J Henderson
- R Zhu
- H Y Ahn
- L Lesko
- S Machado
- N Fleischer
- W Gillespie
- P Lockwood
- A Dorantes
- H Mahayni
- H Malinowski
- K Kumi
- L Tillman
- P Marroum
- R Baweja
- T E Ong-Chen
- V R Uppoor
- V Tammara
|
| rdfs:label
| - Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (en)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (nl)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (sq)
|
| skos:prefLabel
| - Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (en)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (nl)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (sq)
|
| name
| - Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (en)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (nl)
- Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (sq)
|
| title
| |
| title
| - Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| volume
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1007/978-1-4684-6036-0_25
|
| is about
of | |
| is cites work
of | - An engineering approach to biomedical sciences: advanced testing methods and pharmacokinetic modeling
- FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms
- Clinical relevance of dissolution testing in quality by design
- Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations
- In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms
- Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond
- Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations
- From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers.
- In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match?
- In vitro-in vivo correlation: perspectives on model development
- Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices.
- Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis
- Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm
- Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation.
- Quality-by-design: are we there yet?
- A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)